Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Ovarian Neoplasms 3Breast Neoplasms 3Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Brain Neoplasms 2Peripheral Nervous System Diseases 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 3XENP 1595 2Trastuzumab 2Sodium Chloride 2Dexmedetomidine 2Cancer Vaccines 2Adjuvants, Immunologic 2veliparib 1tucatinib 1tipifarnib 1sagopilone 1pembrolizumab 1interferon gamma-1b 1glutathione pegylated liposomal doxorubicin 1elacestrant 1abemaciclib 1Saline Solution 1Rituximab 1Radiotherapy 1Radiation 1RAD1901 1Oncolytic Virotherapy 1Interferon-gamma 1Immunotherapy 1Dasatinib 1Craniotomy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Central Nervous System Diseases × sagopilone × Clear all
NCT00496379 2013-03-14

ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases

Dana-Farber Cancer Institute

Phase 2 Terminated
15 enrolled 10 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡